Holen Sie sich die Stockscreener-App
8.57
5.73%
-0.51
Handel nachbörslich:
8.57
Schlusskurs vom Vortag:
$9.08
Offen:
$9.08
24-Stunden-Volumen:
1.06M
Relative Volume:
1.14
Marktkapitalisierung:
$433.84M
Einnahmen:
$170.44M
Nettoeinkommen (Verlust:
$-193.88M
KGV:
-2.2828
EPS:
-3.7541
Netto-Cashflow:
$-126.38M
1W Leistung:
-1.04%
1M Leistung:
+7.13%
6M Leistung:
-6.96%
1J Leistung:
+30.69%
1-Tages-Spanne:
$8.25
$9.10
1-Wochen-Bereich:
$8.25
$10.77
52-Wochen-Spanne:
$5.035
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Firmenname
Regenxbio Inc
Sektor
Branche
Telefon
240-552-8181
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.57 | 459.66M | 170.44M | -193.88M | -126.38M | -3.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-02-11 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-07 | Fortgesetzt | Raymond James | Outperform |
| 2024-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-06-07 | Eingeleitet | Goldman | Buy |
| 2024-03-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-08 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Fortgesetzt | Raymond James | Outperform |
| 2023-11-01 | Eingeleitet | Stifel | Buy |
| 2023-06-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Wedbush | Neutral |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-01-06 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-14 | Fortgesetzt | Raymond James | Outperform |
| 2019-06-05 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-25 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-11-08 | Bestätigt | BofA/Merrill | Neutral |
| 2018-08-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-23 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-05-09 | Bestätigt | Barclays | Overweight |
| 2018-04-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Eingeleitet | Mizuho | Neutral |
| 2017-11-09 | Fortgesetzt | Morgan Stanley | Overweight |
Alle ansehen
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
Regenxbio Reinforces Case for Its Duchenne Gene Therapy Amid Accelerated Approval Uncertainty - Citeline News & Insights
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Positive interim data for Regenxbio’s gene therapy in DMD - The Pharmaletter
Stifel cuts Regenxbio stock price target to $42 on gene therapy data - Investing.com Nigeria
Insider Sell Alert: Steve Pakola Sells Shares of Regenxbio Inc (RGNX) - GuruFocus
Pakola Steve, Regenxbio CMO, sells $53k in RGNX stock - Investing.com Nigeria
MDA: Vinay away, AA in play for Regenxbio gene therapy? - BioWorld MedTech
Stifel reiterates Regenxbio stock rating on Duchenne trial data - Investing.com
Stifel reiterates Regenxbio stock rating on Duchenne trial data By Investing.com - Investing.com Canada
ROSEN, A RANKED AND LEADING FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Black Hills Pioneer
ROSEN, A RANKED AND LEADING FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study - Stocktwits
Regenxbio reports positive interim data for Duchenne gene therapy By Investing.com - Investing.com Nigeria
Regenxbio reports positive interim data for Duchenne gene therapy - Investing.com Australia
REGENXBIO (RGNX) Reports Promising Interim Results for Duchenne Gene Therapy - GuruFocus
Regenxbio reports new positive interim data from phase I/II Affinity Duchenne® trial of RGX-202 - marketscreener.com
REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PR Newswire
RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - The Malaysian Reserve
Lab Cells Built Different And Therefore Patentable - marketscreener.com
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Investors who lost money on REGENXBIO Inc.(RGNX) should contact Levi & Korsinsky about pending Class ActionRGNX - Morningstar
What is HC Wainwright's Estimate for REGENXBIO Q1 Earnings? - MarketBeat
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP - pharmiweb.com
REGENXBIO Inc. (NASDAQ: RGNX) Investor Alert: Lawsuit seeks to recover Losses for Investors - openPR.com
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Investors who lost money on REGENXBIO Inc.(RGNX) should contact The Gross Law Firm about pending Class ActionRGNX - PR Newswire
Regenxbio stock: Clear Street reiterates Buy on gene therapy data - Investing.com Nigeria
(RGNX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
RGNX'S "Transformational" Promise Became a $2.40 Loss for Investors: Levi & Korsinsky, LLP - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - WFMZ.com
REGENXBIO (NASDAQ:RGNX) Shares Gap UpTime to Buy? - MarketBeat
Regenxbio at Leerink Global Healthcare Conference: Strategic Pipeline Advancements - Investing.com Nigeria
Regenxbio at Leerink Global Healthcare Conference: Strategic Pipeline Advancements By Investing.com - Investing.com Canada
H.C. Wainwright cuts Regenxbio stock price target to $30 - Investing.com India
H.C. Wainwright cuts Regenxbio stock price target to $30 By Investing.com - Investing.com UK
HC Wainwright Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - MarketBeat
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Regenxbio (RGNX): HC Wainwright Maintains Rating, Lowers Price T - GuruFocus
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - PR Newswire
REGENXBIO commends women leadership driving mission on International Womens Day - Traders Union
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript - Insider Monkey
Why REGENXBIO Inc. stock remains a top recommendation2026 Chart Watch & AI Based Trade Execution Alerts - Naître et grandir
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
RBC Capital Reaffirms Their Buy Rating on RegenXBio (RGNX) - The Globe and Mail
RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty - TipRanks
REGENXBIO Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm ... - Bluefield Daily Telegraph
REGENXBIO Inc. Sued for Securities Law Violations – - GlobeNewswire
Finanzdaten der Regenxbio Inc-Aktie (RGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):